Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Dotinurad in Chinese Healthy Subjects
NCT05278676Phase 1Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2022
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of dotinurad in hyperuricemia and gout (3 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Maximum Observed Concentration, Time to Maximum Concentration and 11 more. Started Jul 2022; status: completed.
02
Drugs
dotinurad
03
Conditions
hyperuricemiagout
Beyond the preview
Go deeper on NCT05278676.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05278676.